Tag Archives: healthcare reform

Co-Pay Offset Programs and Health Insurance Marketplaces: Causes for Concern

Co-Pay Offset Programs and Health Insurance Marketplaces As the health insurance marketplaces begin enrollment next week and go-live on January 1, 2014, several issues continue to be a source of significant confusion to manufacturers, payers and millions of consumers who will be purchasing health insurance for the first time through an exchange.  Many of these […]
Posted in Guest Blog, healthcare, Op-Ed | Also tagged , , , , , , , | Leave a comment

Budget Cutters Propose Big Hits on Pharma

By Jill Wechsler, Washington Correspondent. The Obama administration’s budget plan for fiscal year 2014 apparently assumes that the pharmaceutical industry can support Medicare and other health programs through changes in drug coverage and payments. It also relies on industry fees to keep the Food and Drug Administration up and running. Meanwhile, FDA and other public […]
Posted in Guest Blog, healthcare, Op-Ed | Also tagged , , , , , , | Leave a comment

Affordable Care Act: Where's the Sunshine?

Where’s the Sunshine? The Senate Special Committee on Aging is holding a Roundtable discussion on Wed. Sept. 12, 2012 in hopes of spurring action to implement the “Sunshine” provisions of the Affordable Care Act (ACA). Policies for collecting and submitting information on pharma payments to doctors were supposed to be issued by last September (2011), […]
Posted in Guest Blog, healthcare, Op-Ed, Regulatory | Also tagged , , , | Leave a comment

Paul Ryan and Pharma: The Inside Story

by Tom Norton Well, we certainly have a presidential campaign now, don’t we? Good grief. Since Rep. Paul Ryan was named the Republican VP candidate last week, all hell has broken loose!  Given the intensity of the last few days, you’d think the election was tomorrow… And at some point, you do have to ask […]
Posted in FDA, Guest Blog, healthcare, Op-Ed | Also tagged , , , , | 3 Comments

Drug Reimbursement and the "New Medicaid"

by Tom Norton A lot has been written about the “state option” created by the Supreme Court ruling on HCR, and what it means to American medicine. Sorting out an opinion will, to a degree, depend on whom you read and what you believe. But regardless of where you come out on this issue, there […]
Posted in Guest Blog, healthcare, Legal, Market Access, R&D, Regulatory | Also tagged , , , , , , , | 1 Comment
  • Categories

  • Meta